FDA panel to review Theravance, J&J antibiotics in February

01/10/2008 | Forbes · Forbes

A panel of antibiotic experts appointed by the FDA will meet Feb. 27 to review Theravance's injectable antibiotic telavancin for the treatment of skin infections caused by "superbug" bacteria. The next day, the panel will consider the approval of Johnson & Johnson's antibiotic for diabetes-related foot infections, the agency announced.

View Full Article in:

Forbes · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX